QS Research · Michael Burry's Scion Capital analyst template · 2006
3M CO (MMM)
As of 2026-11-17 · 11/15 boxes filled from SEC filings and market data
Report price $181.68 (close 2026-11-16); latest close $177.99 (2026-11-20), -2.0% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -28% · upside +14%
The market is pricing a turnaround at a premium: 26.5x TTM net income and 29.9x tax-normalized operating earnings, with P/S of 3.72x against a 2.9x five-year median, while TTM free cash flow is $2.68B and settlement cash is dated. That supports PASS, not a stronger call, because the evidence cuts both ways. The downside is -29.5% to $128.08, the arithmetic being -15.0% earnings at a compressed P/E of 24.95x (today 29.9x). The upside is +12.0% to $203.48, the arithmetic being +12% earnings at today's P/E of 29.9x. There is no base case: fewer than three comparable peers have a usable multiple and the company's own history gives none, so no comparable peer multiple sets one and a base at today's multiple is today's price by construction.
Key numbers
- Share price: $177.99
- Market cap: $91.97B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $25.25B
- EV / EBITDA (TTM): 16.6x
- P/E (TTM): 26.0x
- FCF yield: 3.0%
- Price / book: 22.29x
- Earnings-quality flags (TTM): none flagged
- P/E, operating (tax-normalized) (TTM): 29.3x
- EV / FCF (TTM): 38.2x
- Revenue growth (latest fiscal year): +1.5%
- ROIC (TTM): 25.8%
- WACC: 7.7%
- Economic profit spread: +18.1 pts
The 15 boxes
- ✓ 1. Long-form business notes
3M runs three reportable segments in the FY2025 10-K (Safety and Industrial, Transportation and Electronics, Consumer) versus four in the FY2020 10-K, which still carried Health Care; the Health Care business and drug delivery are no longer part of the reported segments. The revenue base is roughly a third smaller than the FY2021 peak: $35.35B in FY2021 versus $24.95B in FY2025 and $25.25B TTM to 2026-09-30, and FY2023 contains a $10.69B operating loss and $7.00B net loss that make it unusable as an earnings base. Operating income ran $4.82B in FY2024, $4.63B in FY2025 and $4.74B TTM, but operating cash flow ($1.82B FY2024, $2.31B FY2025, $3.63B TTM) sits far below the FY2020-FY2023 range of $5.59B-$8.11B while buybacks ($3.25B FY2025, $3.78B TTM) exceeded operating cash flow in both periods.
- ○ 2. Competitive advantage
The record shows a margin that holds but does not widen: operating margin 22.2% (FY2020), 20.8% (FY2021), 16.7% (FY2022), 19.6% (FY2024), 18.6% (FY2025) and 18.8% (TTM to Sep 2026), while revenue fell from $35.35B in FY2021 to $24.95B in FY2025 — evidence of pricing power and scale, not of growth. Nothing in the sources quantifies brand, market share, switching costs or customer retention, and no competitor is named; the only supports the filings actually point to are patent/intellectual property protection and a global footprint (56% of 2025 revenue outside the U.S., which the 10-K frames as a risk, not an advantage). Counterweights are visible in the numbers: operating cash flow of $2.31B against net income of $3.25B in FY2025, and a $10.5B–$12.5B PFAS settlement payable 2024 through 2036. The advantage is therefore asserted rather than demonstrated, and its economic rent is being consumed by litigation rather than showing up in cash.
- ✓ 3. 10-Q takeaways
Q3 2026 (quarter ended 2026-09-30) was a modest top-line quarter with a big reported-margin and EPS jump that is not all operating: GAAP sales $6,584 million, up 1.0% YoY (organic +0.2%), GAAP operating margin 23.7% and adjusted 26.2%. Reported GAAP EPS of $2.63 (up 70%) leans on a Solventum stake revaluation, while adjusted EPS of $2.50 rose 12% and FY2026 adjusted EPS guidance was raised to $9.10-$9.15. Cash was $5.2 billion at September 30, 2026 versus $5.9 billion at December 31, 2025, after $3.2 billion of buybacks and $1.9 billion for Madison, with nine-month operating cash flow of $2.0 billion. The 10-Q reports no material change in risk factors.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.